Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9
days, will promote sleep during the following night without significant post-dose thinking
impairment and drowsiness in subjects with primary insomnia.